Curated news about real-world psychedelic research, policy, and developments
VA and HHS launched a new partnership to accelerate psychedelic therapies, expanding research and preparing the VA for future veteran care.
FDA is supporting the development of psychedelic drugs, including new treatments for serious mental health conditions.
It’s a trip doctors hope leads to a breakthrough.
Background Lumpy skin disease (LSD) is an emerging viral disease of cattle in Bangladesh, first reported in 2019. Given the critical role of veterinarians in disease detection, management, and control, it is essential to evaluate their knowledge, attitudes, a…
Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived therapeutics to solve major under-treated mental heal…
Key Points - Compass Pathways said new 26-week Phase 3 COMP006 data support the durability and safety of its psilocybin therapy COMP360 for treatment-resistant depression, reinforcing prior positive late-stage results. - The company is pursuing a rolling FDA…
SCARBOROUGH, Maine, July 9, 2026 /PRNewswire/ -- Organic Payment Gateways today announced a dedicated payment processing service for legal, US-based ketamine clinics. The company expects demand to climb sharply this year. As more medically supervised practice…
Howard Steinberg was a successful, married businessman until it all fell apart. Experimenting with magic mushrooms helped him reconnect with himself.
The US Food and Drug Administration’s (FDA’s) drug review agency has initiated a crackdown on e-commerce sites selling illicit ketamine products to consumers as classic psychedelic therapies edge closer to the market through standard channels. On 7 July 2026,…
Compass Pathways stock crumbled Tuesday despite seemingly positive test results for its psychedelic drug in treatment-resistant depression. The post Why Psychedelics-Tied Compass Pathways Isn't Getting High appeared first on Investor's Business Daily.
WASHINGTON, July 07, 2026 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS ) released an Ibogaine Investigator’s Brochure (IB), a comprehensive scientific and regulatory resource summarizing the current preclinical, safet…
Unapproved New Drugs/Misbranded
Unapproved New Drugs/Misbranded
Unapproved New Drugs/Misbranded
Unapproved New Drugs/Misbranded
Unapproved New Drugs/Misbranded
Unapproved New Drugs/Misbranded
The psychedelic treatment is moving through the FDA clinical trial process in Colorado and elsewhere.
Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived the…
Antidepressants, electroshock, so-called psychedelic-assisted psychotherapy, and even inpatient stays in psychiatric facilities carry far more risks for women, who are inadequately warned of the ri…
TORONTO, July 06, 2026 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced …
156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026...
Psychedelic Nation? Psilocybin Treatments Offer New Hope for People Prozac Hasn’t Helped Psychedelic medications, backed by the White House, may alter the prognosis for people with treatment-resistant depression, but risks remain. Sign up for smart news, insi…
Since getting fired from Jackass Forever in 2020, he's found sobriety and love — with a little help from psychedelics and skateboarding.
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and c…
A single observational case suggests psilocybin may ‘awaken’ cognitive reserve in dementia. But scientists caution controlled trials are needed to know if the drug was the cause. The post Woman With Alzheimer’s Shows Striking Improvement After Taking Magic Mu…
Podcast Transcript In the 1960s, a generation of young people rejected the world their parents had built. They turned away from war, conformity, consumerism, and traditional authority, and embraced music, peace, love, psychedelics, communal living, and a rad…
58 sailors from the U.S. aircraft carrier were punished over an LSD distribution case that began while it was homeported in Japan. Did their network reach into Japanese society?
COMP360 psilocybin therapy could win FDA approval by early 2027. Here's the realistic submission and review timeline for patients with treatment-resistant depression waiting now.
